Triangle Business Journal by Lauren K. Ohnesorge, Staff Writer
Durham-based immuno-therapy development company Argos Therapeutics has added $16 million to its coffers, according to new SEC filings.
The company, which is studying therapies in Lupus, HIV, cancer and other areas with its drug platform, raised the latest equity sum from 24 investors.
In February, the company ditched a bid to go public, electing to look at other options for cash.
Company officials could not immediately be reached for comment regarding the latest fundraiser.
